Savara Inc
SVRA2.585USD
-0.005-0.19%
交易中 （美東）報價延遲15分鐘
446.44M總市值
虧損本益比TTM
關於 Savara Inc 公司
Savara Inc. 是一家臨牀階段的生物製藥公司，專注於罕見呼吸系統疾病。該公司的主導項目莫格拉司亭霧化器溶液 (molgramostim) 是一種吸入性生物製劑，具體來說是一種吸入性粒細胞巨噬細胞集落刺激因子 (GM-CSF)，處於 III 期開發階段，用於治療自身免疫性肺泡蛋白沉積症 (aPAP)。莫格拉司亭是一種重組人 GM-CSF 的吸入製劑，正在開發用於治療 aPAP。莫格拉司亭霧化器溶液每天通過高效霧化器 eFlow 霧化器系統 (PARI Pharma GmbH) 吸入給藥一次。肺泡蛋白沉積症 (PAP) 是一種罕見的肺部疾病，其特徵是肺泡（或氣囊）中積累了表面活性劑。該公司致力於推進 molgramostim aPAP 項目和 III 期 IMPALA-2 臨牀試驗以及外包資本密集型業務。
公司簡介
公司代碼SVRA
公司名稱Savara Inc
上市日期Jun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
員工數量59
證券類型Ordinary Share
年結日Jun 25
公司地址6836 Bee Cave Road
城市AUSTIN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編78746
電話151285113796
網址https://savarapharma.com/
公司代碼SVRA
上市日期Jun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Director
Independent Director
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.36%
Other
55.51%
持股股東
持股股東
佔比
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.36%
Other
55.51%
股東類型
持股股東
佔比
Investment Advisor
33.05%
Venture Capital
22.55%
Hedge Fund
19.34%
Investment Advisor/Hedge Fund
16.33%
Private Equity
6.63%
Corporation
2.71%
Individual Investor
2.67%
Research Firm
1.67%
Bank and Trust
0.25%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
294
182.03M
105.32%
-6.77M
2025Q1
306
176.74M
102.29%
-9.64M
2024Q4
294
173.80M
101.27%
-5.45M
2024Q3
274
169.68M
103.28%
+3.87M
2024Q2
257
157.29M
95.89%
+28.15M
2024Q1
230
131.01M
94.21%
-92.17K
2023Q4
197
123.19M
91.03%
-2.15M
2023Q3
177
120.11M
89.27%
+14.67M
2023Q2
170
92.45M
81.05%
-2.68M
2023Q1
166
87.31M
76.55%
-5.82M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
New Enterprise Associates (NEA)
24.47M
14.16%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
17.60M
10.18%
+3.04M
+20.84%
Mar 31, 2025
TCG Crossover Management, LLC
12.36M
7.15%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
11.46M
6.63%
+2.80M
+32.35%
Mar 31, 2025
Vestal Point Capital, LP
11.00M
6.36%
+225.00K
+2.09%
Mar 31, 2025
VR Adviser, LLC
3.26M
1.88%
+3.26M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.71M
5.04%
+229.91K
+2.71%
Mar 31, 2025
The Vanguard Group, Inc.
8.10M
4.69%
-190.72K
-2.30%
Mar 31, 2025
Nantahala Capital Management, LLC
8.08M
4.67%
+550.12K
+7.31%
Mar 31, 2025
Deerfield Management Company, L.P.
7.96M
4.61%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Texas Capital Texas Small Cap Equity Index ETF
0.39%
iShares Micro-Cap ETF
0.07%
Texas Capital Texas Equity Index ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
0.04%
Nuveen ESG Small-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
iShares Biotechnology ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.91%
Texas Capital Texas Small Cap Equity Index ETF
佔比0.39%
iShares Micro-Cap ETF
佔比0.07%
Texas Capital Texas Equity Index ETF
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
佔比0.04%
Nuveen ESG Small-Cap ETF
佔比0.02%
iShares Russell 2000 Growth ETF
佔比0.02%
iShares Biotechnology ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
